Search PubMed⌕ Search

Biomedical subjects

F Mochizuki

Publications and source records attributed to F Mochizuki.

At least 37 records · Page 2Linked to original sources
PubMed1994

[Evaluation of Helical scanning CT in the diagnosis of pancreatic diseases].

We discuss the usefulness of Helical scanning CT (Helical CT) in the 52 patients with space occupying lesions of the pancreas. Information acquired during the early phase was found to be particularly useful in the evaluation of the extent of pancreatic carcinoma. The diagnostic rate of pancreatic tumors by Helical CT was 78% in 18 operative cases. The detection rate of involvement of the major arteries around the pancreas was compared with angiographic results in 22 cases each other, and the overall accuracy of Helical CT was 100%. On the other hand, the detection rate of PV invasion by Helical CT was compared with histological results in 14 cases, and the overall accuracy was 71.4%. In the cine mode and the multiplanar reconstruction (MPR) image, the courses of the major blood vessels and the degree of invasion into the blood vessels by pancreatic carcinoma could be continuously observed, both enabled reconstruction of the lesion and surrounding areas three dimensionally.

Aged↗
PubMed1994

[The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone].

Long-term oral administration of fluoropyrimidines such as 5-fluorouracil (5-FU) or tegafur is commonly used as an adjuvant chemotherapy for gastric cancer, but the optimal period or optimal total doses of fluoropyrimidines have not been studied. Two hundred cases of macroscopical Stage II and III curatively resected gastric cancer patients were entered in this study, and divided into three groups (6 months group: mitomycin C was given i.v. at day 0 and day 1 and 5-FU tablets were orally administered at a dose of 200 mg/day for 6 months. 12 months group: MMC was given the same as for the 6 months group and 5-FU tablets were administered for 12 months. Surgery alone group: No chemotherapy, operation only). As the result, 185 cases were eligible. There was no significant difference between the 6 months group and the 12 months group among Stage II patients. Although there was also no significant difference between the 2 groups in Stage III patients, the survival curve of 12 months group was always higher than in the 6 months group. When comparing with surgery alone group, 5-year survival of the 12 months group was always higher than in the surgery alone group of Stage III patients; however, the survival rate in the 6 months group was worse than in the surgery alone group at Stage II and III. These results suggest that MMC i.v. and 12 months or over administration of 5-FU tablets is useful for Stage III gastric cancer patients, and that cooperative study is required comparing with surgery alone in Stage II patients.

Administration, Oral↗
PubMed1993

An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.

BACKGROUND: Intraductal mucin-hypersecreting neoplasm of the pancreas (IMHN) is a unique tumor that has a tendency to spread intraductally. The clinical outcome of IMHN generally is far better than that of pancreatic ductal cell carcinoma. Because of the presence of various cell atypia within the same tumor, it sometimes is difficult to make an accurate histopathologic diagnosis and, therefore, predict its biologic behavior. It has been shown that overexpression of c-erbB-2 protein in breast cancer with lymph node metastases is related to a poor prognosis. Overexpression of c-erbB-2 protein has been reported as an infrequent event in pancreatic ductal cell carcinoma, but little is known in the case of IMHN. METHODS: The expression of c-erbB-2 protein was immunohistochemically investigated in the formaldehyde-fixed, paraffin-embedded tissues of 17 cases of IMHN, and 14 cases of pancreatic ductal cell carcinoma (8 cases with lymph node metastasis), using polyclonal and monoclonal c-erbB-2(p185) antibodies by the avidin-biotin method. RESULTS: Both the polyclonal and monoclonal antibodies showed similar immunostaining for the c-erbB-2 product. Overexpression of the c-erbB-2 product was observed frequently in IMHN (13/17), especially in that with moderate- to high-grade cell atypia (12/12), whereas it was detected in only 1 of 14 cases of pancreatic ductal cell carcinoma (1/14). Among eight cases of pancreatic ductal cell carcinoma with lymph node metastases, overexpression of the c-erbB-2 product in metastatic lesions was detected in two, one of whose primary lesions also overexpressed the oncogene product. CONCLUSIONS: These observations suggest the genetic expression of c-erbB-2 is related to the pathogenesis of IMHN.

Adenocarcinoma, Mucinous↗
PubMed1993

The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas.

In order to clarify whether the detection of a point mutation in the c-Ki-ras gene at codon 12 in tumor tissues can assist in predicting the tumor's biological grade of malignancy, two types of tumors were investigated; one was called "carcinoma in the pancreatic head region," and the other was intraductal mucin-hypersecreting neoplasm of the pancreas (IMHN). Dot hybridization and a modified PCR technique developed by Haliassos et al. were employed. Among 16 cases of tumors in the pancreatic head region, the point mutation was detected with a high frequency only in pancreatic ductal cell carcinomas (five out of six cases, 83.3%), but was not detected in extrahepatic bile duct carcinomas (0/5) or in ampullary carcinomas (0/5). In pancreatic ductal cell carcinomas, no relation was found between the occurrence of the point mutation and the histological type of the tumor. Among 20 cases of IMHNs, the point mutation was found in 11 cases (55%). No relation was found between the occurrence of the mutation and the size of IMHNs. However, as the grade of cell atypia increased, the frequency of the mutation tended to become higher. These results suggest that detection of this point mutation might be useful for distinguishing pancreatic ductal cell carcinoma from those of other origins in the pancreatic head region, and for the determination of the histopathological grade of malignancy in IMHNs.

Aged↗
PubMed1993

[Clinical study of gallbladder cancer associated with acute cholecystitis].

The clinical features of gallbladder carcinoma associated with acute cholecystitis and problems in diagnosing this condition by ultrasonography were investigated. Nine cases of gallbladder cancer with acute cholecystitis and 51 cases of gallbladder cancer without acute cholecystitis were reviewed. There were no obvious differences between those two groups as far as depth of invasion, location of cancer, and the prevalence of gallstones were concerned. However, there was a tendency for detection of cancer associated with acute cholecystitis by ultrasound to be more difficult than detection of cancer without acute cholecystitis. Macroscopic examination of resected specimens showed that superficial or flat type cancers tended to occur more often in cases of acute cholecystitis. This is considered to be the main cause of the difficulty in diagnosing such cancer by ultrasound.

Acute Disease↗
PubMed1991

[Point mutation of c-k-ras oncogene at codon 12 in mucin-producing cystic tumor of the pancreas].

The point mutation of c-K-ras oncogene at codon 12 was investigated in 15 cases of mucin-producing cystic tumor of the pancreas by a modified polymerase chain reaction (PCR) method. Three percent formalin-fixed and paraffin embedded materials were employed for the present investigation. These fifteen cases were histopathologically classified into five categories (from group I to V) according to Kozuka's classification which was based on cell atypia of the tumor cells; 5 cases were judged as group V, 4 cases as group IV, and 6 cases as group III. The frequency of point mutation was 5/5 in group V, 3/4 in group IV, and 2/6 in group III. The frequency of point mutation was correlated with morphologically determined cell atypia. Among group III, the point mutation was noticed in the cases with larger tumor size. From genetical point of view, the results indicated more malignant biological feature of mucin-producing cystic tumor of the pancreas than has generally been accepted.

Aged↗
PubMed1991

[Gastric polyp].

Explore the source record for details and available documents.

Adult↗
PubMed1990

[Correlation between ultrasonographic findings and pathological diagnosis of mucin producing tumor of the pancreas].

We reviewed 19 cases of so-called mucin producing tumor of the pancreas ultrasonographically and histopathologically. Conventional ultrasonography could detect 16 cases out of 19 (84%). But its detectability of localized cystic lesion or papillary projection in the cystic lesion was 68%. On the contrary, endoscopic ultrasonography could visualize such changes in 93% of the cases. In the case which have neoplastic change, it is considered that the portion showing papillary proliferation is correspondent to the ultrasonographic findings of irregularity of the wall of the pancreatic duct or thickened septum-like structure. In the cases which are diagnosed as hyperplasia, the cystic lesions are delineated as having smooth and thin septum-like structure.

Adenocarcinoma↗
PubMed1989

Carcinoid tumor of the bile duct: case report.

Carcinoid tumor of the bile duct is extremely rare. Ten cases have been reported in the literature. This report describes the eleventh case. A 55-year-old woman was hospitalized with biliary stenosis. Sonography (US) and computed tomography (CT) demonstrated a tumor in the upper common hepatic duct (CHD). Percutaneous transhepatic cholangiography showed extraluminal growth of the tumor. The tumor was resected and histologic examination showed carcinoid tumor of the common hepatic duct.

Bile Duct Neoplasms↗
PubMed1989

[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].

Chemosensitivity of human head and neck tumor was evaluated by human tumor clonogenic assay. Among eight of head and neck tumors seven squamous cell carcinomas such as tongue, gingiva, maxillary sinus, pharynx and one malignant fibrous histiocytoma (MFH) of maxillary sinus and four anti-cancer agents BLM, CDDP, 5-FU and MMC were used. Five of eight tumors were succeeded to evaluate the sensitivity. Positive rates except MFH were BLM 100% (3/3), CDDP 25% (1/4), 5-FU 33% (1/3). These results are similar to recent clinical experiments except CDDP.

Bleomycin↗
PubMed1989

[Radio- and radio-chemosensitivity of human head and neck cancer cell line detected by human tumor clonogenic assay].

The radiosensitivity and radio-chemosensitivity of 3 series of human cancer cell lines were evaluated by human tumor clonogenic assay. The sources of cell lines were gingiva carcinoma (Ca9-22), uterus carcinoma (Hela) and gastric carcinoma (MKN-45). BLM and CDDP were used, and chemosensitivity of gingiva carcinoma tended to be higher than other cell lines. Radiosensitivity was same as MKN-45. Isobologram were employed for quantitation of the interaction between the irradiation and anti-cancer agents. In Ca9-22, the interaction of between gamma-rays, BLM and CDDP was supra-additive. Hela was also supra-additive, but in MKN-45, the interaction of between gamma-rays and BLM was sub-additive.

Bleomycin↗
PubMed1989

[Randomized-controlled study of treatment with UFT-MMC or UFT-ACR in advanced gastric cancer. Tohoku Study Group of Cancer Treatment for the Digestive Organs].

The effect of UFT-MMC- or UFT-ACR-therapy on the unresectable or recurrent gastric cancer was studied by a multicenter, randomized-controlled trial. All the patients who were randomly divided into the two groups were administered orally with 400 or 600 mg/day of UFT everyday. In addition, the UFT-MMC group was intravenously injected weekly for three weeks and then triweekly after six weeks with 6 or 8 mg/body of MMC, while the UFT-ACR group was intravenously injected with 20 mg/body of ACR for 5 serial-days every three weeks. Out of 88 cases registered, 75 (85.2%) were evaluable, consisting of 40 (31 complete cases) in UFT-MMC and 35 (27 complete cases) in UFT-ACR. There was no difference in various background factors between the two groups. PR, NC and PD was 10/31, 15/31 and 6/31 in the UFT-MMC group, whereas 0/27, 22/27 and 5/27 in the UFT-ACR group, respectively. The efficacy in the former group was higher, though not significant (U-test, p = 0.052), than that in the latter group. However, there was no difference in the 50% survival time (4.9 months in UFT-MMC vs. 5.4 months in UFT-ACR) of the either group.

Aclarubicin↗